Non-Small Lung Cell Cancer clinical trials at University of California Health

1 research study open to eligible people

BBO-11818 in Adult Subjects With KRAS Mutant Cancer
open to eligible people ages 18 years and up
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
at UCSD

Last updated: August 1, 2025